Your browser doesn't support javascript.
loading
Fertility preservation in women with benign gynaecological conditions.
Santulli, Pietro; Blockeel, Christophe; Bourdon, Mathilde; Coticchio, Giovanni; Campbell, Alison; De Vos, Michel; Macklon, Kirsten Tryde; Pinborg, Anja; Garcia-Velasco, Juan A.
Afiliación
  • Santulli P; Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Paris, France.
  • Blockeel C; Faculté de Médecine, Sorbonne Paris Cité, Paris, France.
  • Bourdon M; Department of Gynecology and Obstetrics II and Reproductive Medicine (Professor Chapron), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.
  • Coticchio G; Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016 (Professor Batteux), Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
  • Campbell A; Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • De Vos M; Department of Obstetrics and Gynaecology, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Macklon KT; Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Paris, France.
  • Pinborg A; Faculté de Médecine, Sorbonne Paris Cité, Paris, France.
  • Garcia-Velasco JA; Department of Gynecology and Obstetrics II and Reproductive Medicine (Professor Chapron), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.
Hum Reprod Open ; 2023(2): hoad012, 2023.
Article en En | MEDLINE | ID: mdl-37124950
ABSTRACT
Although a wealth of data has been published regarding fertility preservation (FP) in women with malignant diseases who receive gonadotoxic treatment, the role of FP in non-malignant conditions has been studied to a much lesser extent. These include benign haematological, autoimmune, and genetic disorders, as well as a multitude of benign gynaecological conditions (BGCs) that may compromise ovarian reserve and/or reproductive potential due to pathogenic mechanisms or as a result of medical or surgical treatments. Alongside accumulating data that document the reproductive potential of cryopreserved oocytes and ovarian tissue, there is potential interest in FP for women with BGCs at risk of infertility; however, there are currently insufficient data about FP in women with BGCs to develop guidelines for clinical practice. The purpose of this article is to appraise the available evidence regarding FP for BGC and discuss potential strategies for FP based on estimated ovarian impairment and on short-term and long-term reproductive goals of patients. Cost-effectiveness considerations and patients' perspectives will also be discussed.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Hum Reprod Open Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Hum Reprod Open Año: 2023 Tipo del documento: Article